Inhibitors of the Autotaxin-Lysophosphatidic Acid Axis and Their Potential in the Treatment of Interstitial Lung Disease: Current Perspectives

Sabrina Zulfikar, Sarah Mulholland, Huzaifa Adamali, Shaney L Barratt

Research output: Contribution to journalReview article (Academic Journal)peer-review


Idiopathic pulmonary fibrosis is a progressive fibrosing interstitial lung disease for which there is no known cure. Currently available therapeutic options have been shown at best to slow the progression of the disease and thus there remains an urgent unmet need to identify new therapies. In this article, we will discuss the mechanisms of action, pre-clinical and clinical trial data surrounding inhibitors of the autotaxin-lysophosphatidic acid axis, which show promise as emerging novel therapies for fibrotic lung disease.

Original languageEnglish
Pages (from-to)97-108
Number of pages12
JournalClinical pharmacology : advances and applications
Publication statusPublished - 2020

Cite this